Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high ...
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an ...
Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback